Detalhe da pesquisa
1.
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
Transplant Cell Ther
; 27(9): 788-794, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34214738